Related references
Note: Only part of the references are listed.The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic
Andrew Hill et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2023)
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Teresa Brevini et al.
NATURE (2023)
EDP-297: A novel, farnesoid X receptor agonist-Results of a phase I study in healthy subjects
Christine Marotta et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)
Nuclear farnesoid X receptor attenuates acute kidney injury through fatty acid oxidation
Sujuan Xu et al.
KIDNEY INTERNATIONAL (2022)
Renal Farnesoid X Receptor improves high fructose-induced salt-sensitive hypertension in mice by inhibiting DNM3 to promote nitro oxide production
Yeyan Zhu et al.
JOURNAL OF HYPERTENSION (2022)
A multiomics disease progression signature of low-risk ccRCC
Philipp Strauss et al.
SCIENTIFIC REPORTS (2022)
Farnesoid X receptor protects against cisplatin-induced acute kidney injury by regulating the transcription of ferroptosis-related genes
Dong-Hyun Kim et al.
REDOX BIOLOGY (2022)
Genetic deletion of the nuclear factor of activated T cells 5 in collecting duct principal cells causes nephrogenic diabetes insipidus
Federica Petrillo et al.
FASEB JOURNAL (2022)
Farnesoid X Receptor Overexpression Decreases the Migration, Invasion and Angiogenesis of Human Bladder Cancers via AMPK Activation and Cholesterol Biosynthesis Inhibition
Chien-Rui Lai et al.
CANCERS (2022)
Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
Stefan Traussnigg et al.
WIENER KLINISCHE WOCHENSCHRIFT (2021)
Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model
Sang Youb Han et al.
ACTA DIABETOLOGICA (2021)
Farnesoid X receptor promotes renal ischaemia-reperfusion injury by inducing tubular epithelial cell apoptosis
Yao Xu et al.
CELL PROLIFERATION (2021)
Research in brief
Holly Baker
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
The critical role of FXR is associated with the regulation of autophagy and apoptosis in the progression of AKI to CKD
Dong-Hyun Kim et al.
CELL DEATH & DISEASE (2021)
Identification and characterization of novel splice variants of human farnesoid X receptor
Enni-Kaisa Mustonen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2021)
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study
Robin Erken et al.
JOURNAL OF VIRAL HEPATITIS (2021)
Chronic kidney disease
Kamyar Kalantar-Zadeh et al.
LANCET (2021)
Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist
Tong Zhao et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2021)
Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver-Distributed Farnesoid X-Receptor Agonist TERN-101 in Healthy Volunteers
Yujin Wang et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
A naturally occurring FXR agonist, alisol B 23-acetate, protects against renal ischemia-reperfusion injury
Zhi-Lin Luan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2021)
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
Donatella Chianelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway
Yu-Lien Tsai et al.
CLINICAL SCIENCE (2020)
Promotion of lipogenesis by PPARγ-activated FXR expression in adipocytes
Saki Shinohara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis
Larissa Akeme Nakano et al.
BMC GASTROENTEROLOGY (2020)
trans-Chalcone inhibits high-fat diet-induced disturbances in FXR/SREBP-1c/FAS and FXR/Smad-3 pathways in the kidney of rats
Mohammad Reza Alipour et al.
JOURNAL OF FOOD BIOCHEMISTRY (2020)
Activation of farnesoid X receptor (FXR) induces crystallin zeta expression in mouse medullary collecting duct cells
Gulzar Alam et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2020)
FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet
Amar B. Singh et al.
PHYSIOLOGICAL REPORTS (2020)
Farnesoid X receptor and liver X receptors regulate Oct3/4 expression by multiple feedback regulating system in normal renal-derived cells and renal adenocarcinoma cells
Tomofumi Fujino et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2020)
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Zobair Younossi et al.
HEPATOLOGY (2019)
Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor
Dong Renchan et al.
PHYTOMEDICINE (2019)
The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction
Shen Li et al.
FASEB JOURNAL (2019)
Potential of Zerumbone as an Anti-Cancer Agent
Sosmitha Girisa et al.
MOLECULES (2019)
Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis
Sangwon Byun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Src-mediated crosstalk between FXR and YAP protects against renal fibrosis
Dong-Hyun Kim et al.
FASEB JOURNAL (2019)
FXR overexpression alters adipose tissue architecture in mice and limits its storage capacity leading to metabolic derangements[S]
Tim van Zutphen et al.
JOURNAL OF LIPID RESEARCH (2019)
Roux-en-Y gastric bypass enhances insulin secretion in type 2 diabetes via FXR-mediated TRPA1 expression
Xiangchen Kong et al.
MOLECULAR METABOLISM (2019)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Michael Trauner et al.
HEPATOLOGY (2019)
FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake
Ling Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Xiaoxin X. Wang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers
Amani Al-Khaifi et al.
GASTROENTEROLOGY (2018)
Pharmacokinetics, pharmacodynamics, and safety of EDP-305, in healthy and presumptive NAFLD subjects
A. Ahmad et al.
JOURNAL OF HEPATOLOGY (2018)
Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress
Sujuan Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury
Jin-Bo Zhu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
The nuclear receptor superfamily: A structural perspective
Emily R. Weikum et al.
PROTEIN SCIENCE (2018)
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Philipp Schwabl et al.
JOURNAL OF HEPATOLOGY (2017)
Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy
Andi Marquardt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Hepatocyte Nuclear Factor-1β Regulates Urinary Concentration and Response to Hypertonicity
Karam Aboudehen et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Farnesoid X receptor regulates the growth of renal adenocarcinoma cells without affecting that of a normal renal cell-derived cell line
Tomofumi Fujino et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2017)
Quantitative Proteomics and Targeted Fatty Acids Analysis Reveal the Damage of Triptolide in Liver and Kidney
Menglin Li et al.
PROTEOMICS (2017)
Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation
Yimeng Zhang et al.
TOXICOLOGY (2017)
Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage
Zhibo Gai et al.
SCIENTIFIC REPORTS (2017)
Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice
Zhibo Gai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy
Baoshang Zhou et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Activation of FXR protects against renal fibrosis via suppressing Smad3 expression
Kai Zhao et al.
SCIENTIFIC REPORTS (2016)
Oct3/4 directly regulates expression of E2F3a in mouse embryonic stem cells
Dai Kanai et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists
Kebiao Song et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Michaela Mueller et al.
JOURNAL OF HEPATOLOGY (2015)
Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats
Chenyu Li et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2015)
FXR expression is associated with dysregulated glucose and lipid levels in the offspring kidney induced by maternal obesity
Sarah J. Glastras et al.
NUTRITION & METABOLISM (2015)
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Changtao Jiang et al.
NATURE COMMUNICATIONS (2015)
Glucose Sensing O-GlcNAcylation Pathway Regulates the Nuclear Bile Acid Receptor Farnesoid X Receptor (FXR)
Wahiba Berrabah et al.
HEPATOLOGY (2014)
Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk
Fleur Lien et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Farnesoid X Receptor Ligand Prevents Cisplatin-Induced Kidney Injury by Enhancing Small Heterodimer Partner
Eun Hui Bae et al.
PLOS ONE (2014)
Hepatic Farnesoid X-Receptor Isoforms α2 and α4 Differentially Modulate Bile Salt and Lipoprotein Metabolism in Mice
Marije Boesjes et al.
PLOS ONE (2014)
Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice
Xiaoyan Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Hepatic glucose sensing is required to preserve β cell glucose competence
Pascal Seyer et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes
Sandrine Caron et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
FXR Agonist INT-747 Upregulates DDAH Expression and Enhances Insulin Sensitivity in High-Salt Fed Dahl Rats
Yohannes T. Ghebremariam et al.
PLOS ONE (2013)
Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
Yongjie Ma et al.
PHARMACEUTICAL RESEARCH (2013)
Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
Fei Li et al.
NATURE COMMUNICATIONS (2013)
Unbinding Pathways of GW4064 from Human Farnesoid X Receptor As Revealed by Molecular Dynamics Simulations
Weihua Li et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
Effect of Chenodeoxycholic Acid on Fibrosis, Inflammation and Oxidative Stress in Kidney in High-Fructose-Fed Wistar Rats
Zhijuan Hu et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation
Anatoly Kreinin et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2011)
Nuclear receptors as drug targets for metabolic disease
Ira G. Schulman
ADVANCED DRUG DELIVERY REVIEWS (2010)
The bile acid sensor FXR regulates insulin transcription and secretion
Barbara Renga et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
Xiaoxin X. Wang et al.
DIABETES (2010)
A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia
Mark J. Evans et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2009)
FXR Acetylation Is Normally Dynamically Regulated by p300 and SIRT1 but Constitutively Elevated in Metabolic Disease States
Jongsook Kim Kemper et al.
CELL METABOLISM (2009)
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
Songwen Zhang et al.
JOURNAL OF HEPATOLOGY (2009)
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria
Xiaoxin X. Wang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Cedric Langhi et al.
FEBS LETTERS (2008)
Phosphorylation of Farnesoid X Receptor by Protein Kinase C Promotes Its Transcriptional Activity
Romain Gineste et al.
MOLECULAR ENDOCRINOLOGY (2008)
Analysis of nuclear receptor pseudogenes in vertebrates: How the silent tell their stories
Zhengdong D. Zhang et al.
MOLECULAR BIOLOGY AND EVOLUTION (2008)
Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy
Tao Jiang et al.
DIABETES (2007)
Coordinated induction of bile acid detoxification and alternative elimination in mice:: role of FXR-regulated organic solute transporter-α/β in the adaptive response to bile acids
G Zollner et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Farnesoid X receptor is essential for normal glucose homeostasis
K Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Fxr-/- mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids
HU Marschall et al.
JOURNAL OF LIPID RESEARCH (2006)
The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes
JF Landrier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
YQ Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Excerpts from the United States Renal Data System 2004 Annual Data Report: Atlas of end-stage renal disease in the United States - Perface
AJ Collins et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR
YQ Zhang et al.
GENES & DEVELOPMENT (2004)
Regulation of drug transporters by the farnesoid X receptor in mice
Tornoji Maeda et al.
MOLECULAR PHARMACEUTICS (2004)
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine
G Zollner et al.
JOURNAL OF HEPATOLOGY (2003)
Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter
F Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterol
K Otte et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis
G Lambert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation
YQ Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA
M Nakahara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Regulation of multidrug resistance-associated protein 2 (ABCC2) by nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor
HR Kast et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Nuclear receptor minireview series
JM Olefsky
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor
M Ananthanarayanan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp
LA Denson et al.
GASTROENTEROLOGY (2001)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
B Goodwin et al.
MOLECULAR CELL (2000)
Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor
BA Laffitte et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells
H Niwa et al.
NATURE GENETICS (2000)
Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors
TT Lu et al.
MOLECULAR CELL (2000)
Share Paper
